Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination Therapy
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of an international patent application for a pioneering combination therapy of Ibogaine and N-Acylethanolamines. This innovative treatment, developed in collaboration with SciSparc (Nasdaq: SPRC), aims to enhance safety and efficacy in mental health and addiction care.
Ibogaine, derived from the Tabernanthe iboga shrub, has shown promise in treating various substance use disorders. The combination with N-Acylethanolamines, including Palmitoylethanolamide (PEA), is expected to further improve the therapy's effectiveness and safety profile. This development underscores Clearmind's commitment to leadership in the psychedelics space and its focus on providing safe solutions for unmet mental health needs.
Clearmind Medicine Inc. (Nasdaq: CMND) ha annunciato la pubblicazione di una domanda di brevetto internazionale per una terapia combinata pionieristica di Ibogaine e N-Acylethanolamines. Questo trattamento innovativo, sviluppato in collaborazione con SciSparc (Nasdaq: SPRC), mira a migliorare la sicurezza e l'efficacia nella cura della salute mentale e delle dipendenze.
L'Ibogaine, derivato dall'arbusto Tabernanthe iboga, ha mostrato promesse nel trattamento di vari disturbi da uso di sostanze. La combinazione con N-Acylethanolamines, incluso il Palmitoilethanolamide (PEA), dovrebbe ulteriormente migliorare l'efficacia e il profilo di sicurezza della terapia. Questo sviluppo sottolinea l'impegno di Clearmind nella leadership nel campo dei psichedelici e la sua attenzione a fornire soluzioni sicure per le esigenze insoddisfatte di salute mentale.
Clearmind Medicine Inc. (Nasdaq: CMND) ha anunciado la publicación de una solicitud de patente internacional para una terapia combinada pionera de Ibogaína y N-Aciletilamidas. Este tratamiento innovador, desarrollado en colaboración con SciSparc (Nasdaq: SPRC), tiene como objetivo mejorar la seguridad y la eficacia en el cuidado de la salud mental y la adicción.
La Ibogaína, derivada del arbusto Tabernanthe iboga, ha mostrado promesas en el tratamiento de varios trastornos por uso de sustancias. Se espera que la combinación con N-Aciletilamidas, incluyendo el Palmitoiletanolamida (PEA), mejore aún más la efectividad y el perfil de seguridad de la terapia. Este desarrollo subraya el compromiso de Clearmind con el liderazgo en el ámbito de los psicodélicos y su enfoque en proporcionar soluciones seguras para las necesidades no satisfechas de salud mental.
Clearmind Medicine Inc. (Nasdaq: CMND)는 Ibogaine과 N-Acylethanolamines의 혁신적인 결합 요법에 대한 국제 특허 출원 발표를 했습니다. SciSparc와 공동으로 개발한 이 혁신적인 치료법은 정신 건강과 중독 치료에서 안전성과 효능을 향상시키는 것을 목표로 하고 있습니다.
타베란테 아이보가 덤불에서 유래한 이보가인(Ibogaine)은 다양한 물질 사용 장애 치료에 대한 가능성을 보여주었습니다. 팔미토일에탄올아미드(PEA)를 포함한 N-Acylethanolamines와의 결합은 치료법의 효과와 안전성을 더욱 향상시킬 것으로 기대됩니다. 이 발전은 클리어마인드의 사이키델릭 분야에서의 리더십 의지를 강조하며, 충족되지 않은 정신 건강 요구 사항에 대한 안전한 솔루션 제공에 중점을 두고 있음을 나타냅니다.
Clearmind Medicine Inc. (Nasdaq: CMND) a annoncé la publication d'une demande de brevet international pour une thérapie combinée pionnière de l'Ibogaïne et des N-Acylethanolamines. Ce traitement innovant, développé en collaboration avec SciSparc (Nasdaq: SPRC), vise à améliorer la sécurité et l'efficacité dans le domaine de la santé mentale et des soins d'addiction.
L'Ibogaïne, dérivée de l'arbuste Tabernanthe iboga, a montré des promesses dans le traitement de divers troubles liés à la consommation de substances. La combinaison avec les N-Acylethanolamines, y compris le Palmitoyléthanolamide (PEA), devrait améliorer encore l'efficacité et le profil de sécurité de la thérapie. Ce développement souligne l'engagement de Clearmind envers le leadership dans le domaine des psychédéliques et son attention à fournir des solutions sûres pour les besoins non satisfaits en matière de santé mentale.
Clearmind Medicine Inc. (Nasdaq: CMND) hat die Veröffentlichung eines internationalen Patentantrags für eine bahnbrechende Kombinationstherapie mit Ibogaine und N-Acylethanolaminen angekündigt. Diese innovative Behandlung, die in Zusammenarbeit mit SciSparc (Nasdaq: SPRC) entwickelt wurde, zielt darauf ab, Sicherheit und Wirksamkeit in der psychischen Gesundheits- und Suchtbehandlung zu verbessern.
Ibogaine, das aus dem Strauch Tabernanthe iboga gewonnen wird, hat sich als vielversprechend bei der Behandlung verschiedener Substanzgebrauchsstörungen erwiesen. Die Kombination mit N-Acylethanolaminen, einschließlich Palmitoylethanolamid (PEA), wird voraussichtlich die Wirksamkeit und das Sicherheitsprofil der Therapie weiter verbessern. Diese Entwicklung unterstreicht Clearminds Engagement für Führungspositionen im Bereich der Psychedelika und den Fokus auf die Bereitstellung sicherer Lösungen für unerfüllte Bedürfnisse im Bereich der psychischen Gesundheit.
- Publication of international patent application for Ibogaine and N-Acylethanolamines combination therapy
- Potential enhancement of safety and efficacy in mental health and addiction treatment
- Collaboration with SciSparc to develop innovative therapies
- Expansion of Clearmind's patent portfolio in the psychedelics space
- Reports of fatalities and adverse events associated with Ibogaine use
This patent application represents a significant step forward in the development of safer and more effective psychedelic-based therapies. The combination of Ibogaine and N-Acylethanolamines could potentially address the safety concerns associated with Ibogaine while enhancing its therapeutic efficacy.
The collaboration between Clearmind and SciSparc demonstrates a strategic approach to drug development, leveraging the expertise of both companies. This could accelerate the path to market and increase the chances of regulatory approval. The focus on treating substance use disorders, particularly opioid and cocaine addiction, addresses a critical unmet need in the healthcare sector.
Investors should note that while this patent application is promising, it's still early-stage research. The road to commercialization is long and uncertain in the biotech industry, especially for novel psychedelic therapies. However, Clearmind's proactive approach to building a diverse patent portfolio could provide significant value in the long term.
Clearmind's patent application for the Ibogaine-N-Acylethanolamines combination therapy could be a game-changer in the addiction treatment market. The global substance abuse treatment market is projected to reach
The collaboration with SciSparc is strategically sound, combining Clearmind's expertise in psychedelic compounds with SciSparc's focus on central nervous system disorders. This synergy could lead to faster development and potentially lower R&D costs. However, investors should be aware that the psychedelics industry faces regulatory hurdles and public perception challenges.
While the patent application is a positive step, it's important to note that Clearmind is still in the clinical stage. The company's ability to successfully navigate clinical trials and secure FDA approval will be important for long-term success and investor returns.
Innovative drug treatment developed in collaboration with SciSparc
aims to enhance safety and efficacy in mental health and addiction care
Vancouver, Canada, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its pioneering combination therapy of Ibogaine and N-Acylethanolamines.
Ibogaine, a key compound derived from the root of Tabernanthe iboga, a shrub native to West and Central Africa, has shown promise in human clinical trials for treating opioid use disorder (OUD), cocaine use disorder (CUD), and other substance use disorders (SUD). As a result, Ibogaine is considered a potentially effective anti-addiction agent.
The patent application follows innovative developments from Clearmind’s successful collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a clinical-stage specialty pharmaceutical company focused on treatments for central nervous system disorders. Together, the two companies are researching innovative combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA).
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented: “The publication of this patent highlights Clearmind’s commitment to leadership in the psychedelics space through building a diverse patent portfolio, featuring technologies with varying timelines to market. Most importantly, we aim to provide safe and effective solutions for mental health conditions that currently have unmet needs. While treatments with Ibogaine are generally considered safe under proper medical supervision, there have been reports of fatalities or adverse events associated with the ingestion of iboga plant material or Ibogaine. We believe that combining Ibogaine with Palmitoylethanolamide will further enhance the efficacy and safety of this promising therapy.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
About SciSparc Ltd.
SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses Clearmind’s commitment to be a leader in the psychedelics space by creating a diverse patent portfolio, which contains various technologies with different times to market, but more importantly provides efficacious and safe solutions to various mental health conditions with unmet needs. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the new patent application announced by Clearmind Medicine (CMND)?
How might the Ibogaine combination therapy benefit patients according to Clearmind (CMND)?
What is the collaboration between Clearmind Medicine (CMND) and SciSparc focused on?
What potential risks are associated with Ibogaine treatment, as mentioned by Clearmind (CMND)?
